Recent data issuing the prognostic impact of hypercalcemia on outcome of aerodigestive tract cancers are spare. To assess the prognosis and the survival of head and neck cancer patients with hypercalcemia, we reviewed 136 recent successive cases, including also oesophageal and lung cancers. Data were collected from a retrospective database (July 2002–January 2004). Hypercalcemia was defined by calcemia level above 2.55mmol/l. Univariate analysis for prognosis was performed with Mann–Whitney test (continuous variables) and Odd Ratio with 95% confidence interval (categorical variables). The primary locations were : oropharynx and oral cavity (79, 58%), hypopharynx (13, 9.5%), larynx (10, 7.3%), oesophagus (17, 12.5%) and lung (17, 12.5%). There were 23 females and 123 males, with a median age of 53 (18–86). The incidence of bone metastasis was low: 20/136, 14.5%. At cancer diagnosis, 32 hypercalcemia were observed. With a median follow-up of 88 days (2–553), we observed 98 deaths (overall mortality=72%). The median overall survival was 35 days (2–553+). The pejorative prognostic factors were: male gender (OR=2.64 CI 95% 1.07–6.82), age inferior to 50 (OR=2.67 CI 95% 1.23–5.8), presence of distant metastasis (OR=4.45 CI 95% 1.8–11.01), elevation of alkaline phosphatases (OR=7 CI 95% 2.73–17.9) and need of hospitalization for intravenous hydratation (OR=5.11 CI 95% 1.99–13.17). We observed 39 recurrences of hypercalcemia. The predictive factors for recurrence of hypercalcemia were: age superior to 50 (OR=4.61 CI 95% 2.02–10.52), male gender (OR=38.22 CI 95% 12.2–89), calcemia level superior to 2.7mmol/l (OR=3.08 CI 95% 1.42–6.64) and absence of diphosphonates (bisphosphonates: OR=2.16 CI 95% 1.01–4.63). Despite use of diphosphonates (infusions of pamidronate), hypercalcemia is associated with very poor prognosis. Tumour location and level of calcemia had no prognostic value.